guest ::
| Home > Publications database > Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. > print |
| Home > Publications database > Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. > print |
| 001 | 285254 | ||
| 005 | 20240229155105.0 | ||
| 024 | 7 | _ | |a 10.1186/s40478-023-01669-9 |2 doi |
| 024 | 7 | _ | |a pmid:37932833 |2 pmid |
| 024 | 7 | _ | |a altmetric:156239364 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-02289 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Rautajoki, Kirsi J |0 0000-0001-6549-7810 |b 0 |
| 245 | _ | _ | |a Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. |
| 260 | _ | _ | |a London |c 2023 |b Biomed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1699430420_26040 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a As the progression of low-grade diffuse astrocytomas into grade 4 tumors significantly impacts patient prognosis, a better understanding of this process is of paramount importance for improved patient care. In this project, we analyzed matched IDH-mutant astrocytomas before and after progression to grade 4 from six patients (discovery cohort) with genome-wide sequencing, 21 additional patients with targeted sequencing, and 33 patients from Glioma Longitudinal AnalySiS cohort for validation. The Cancer Genome Atlas data from 595 diffuse gliomas provided supportive information. All patients in our discovery cohort received radiation, all but one underwent chemotherapy, and no patient received temozolomide (TMZ) before progression to grade 4 disease. One case in the discovery cohort exhibited a hypermutation signature associated with the inactivation of the MSH2 and DNMT3A genes. In other patients, the number of chromosomal rearrangements and deletions increased in grade 4 tumors. The cell cycle checkpoint gene CDKN2A, or less frequently RB1, was most commonly inactivated after receiving both chemo- and radiotherapy when compared to other treatment groups. Concomitant activating PDGFRA/MET alterations were detected in tumors that acquired a homozygous CDKN2A deletion. NRG3 gene was significantly downregulated and recurrently altered in progressed tumors. Its decreased expression was associated with poorer overall survival in both univariate and multivariate analysis. We also detected progression-related alterations in RAD51B and other DNA repair pathway genes associated with the promotion of error-prone DNA repair, potentially facilitating tumor progression. In our retrospective analysis of patient treatment and survival timelines (n = 75), the combination of postoperative radiation and chemotherapy (mainly TMZ) outperformed radiation, especially in the grade 3 tumor cohort, in which it was typically given after primary surgery. Our results provide further insight into the contribution of treatment and genetic alterations in cell cycle, growth factor signaling, and DNA repair-related genes to tumor evolution and progression. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Cancer genomics |2 Other |
| 650 | _ | 7 | |a Diffuse glioma |2 Other |
| 650 | _ | 7 | |a Homologous recombination repair |2 Other |
| 650 | _ | 7 | |a Longitudinal analysis |2 Other |
| 650 | _ | 7 | |a Microhomology-mediated end-joining |2 Other |
| 650 | _ | 7 | |a Non-homologous end-joining |2 Other |
| 650 | _ | 7 | |a RNA-sequencing |2 Other |
| 650 | _ | 7 | |a Secondary glioblastoma |2 Other |
| 700 | 1 | _ | |a Jaatinen, Serafiina |b 1 |
| 700 | 1 | _ | |a Hartewig, Anja |b 2 |
| 700 | 1 | _ | |a Tiihonen, Aliisa M |b 3 |
| 700 | 1 | _ | |a Annala, Matti |b 4 |
| 700 | 1 | _ | |a Salonen, Iida |b 5 |
| 700 | 1 | _ | |a Valkonen, Masi |b 6 |
| 700 | 1 | _ | |a Simola, Vili |b 7 |
| 700 | 1 | _ | |a Vuorinen, Elisa M |b 8 |
| 700 | 1 | _ | |a Kivinen, Anni |b 9 |
| 700 | 1 | _ | |a Rauhala, Minna J |b 10 |
| 700 | 1 | _ | |a Nurminen, Riikka |b 11 |
| 700 | 1 | _ | |a Maass, Kendra K |0 P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7 |b 12 |u dkfz |
| 700 | 1 | _ | |a Lahtela, Sirpa-Liisa |b 13 |
| 700 | 1 | _ | |a Jukkola, Arja |b 14 |
| 700 | 1 | _ | |a Yli-Harja, Olli |b 15 |
| 700 | 1 | _ | |a Helén, Pauli |b 16 |
| 700 | 1 | _ | |a Pajtler, Kristian W |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |b 17 |u dkfz |
| 700 | 1 | _ | |a Ruusuvuori, Pekka |b 18 |
| 700 | 1 | _ | |a Haapasalo, Joonas |b 19 |
| 700 | 1 | _ | |a Zhang, Wei |b 20 |
| 700 | 1 | _ | |a Haapasalo, Hannu |b 21 |
| 700 | 1 | _ | |a Nykter, Matti |b 22 |
| 773 | _ | _ | |a 10.1186/s40478-023-01669-9 |g Vol. 11, no. 1, p. 176 |0 PERI:(DE-600)2715589-4 |n 1 |p 176 |t Acta Neuropathologica Communications |v 11 |y 2023 |x 2051-5960 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:285254 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ACTA NEUROPATHOL COM : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T09:09:14Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T09:09:14Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T09:09:14Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-26 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ACTA NEUROPATHOL COM : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-10-26 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-10-26 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|